An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

• Status: Completed
• Trial end date: 2013-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label extension study for patients who participated in the BPS-MR-PAH-201 study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lung Biotechnology PBC
• Treatments: Beraprost; Epoprostenol

Criteria

Inclusion Criteria:

• Patients who remained on study drug and completed all assessments during the Treatment Phase of Study BPS-MR-PAH-201 are eligible for this study.

• Female patients must either be physiologically incapable of childbearing or be practicing an acceptable method of birth control (e.g. approved hormonal contraceptive, barrier method, such as condom or diaphragm, used with a spermicide, or an intrauterine device).

Exclusion Criteria:

• Patients who discontinued study drug during the previous study (BPS-MR-PAH-201) for any reason (e.g. treatment related adverse events) are not eligible for entry into this study.

• Patients who are pregnant or lactating are excluded from participation in the open-label extension.